Tag Archives: RESI

RESI@TMCx Innovation Challenge Winners Announced

14 Apr

By Nono Hu, Director of Marketing, LSN

This week at RESI@TMCx, thirty companies from the biotech, medical device, diagnostic and healthcare IT sectors competed in the RESI Innovation Challenge. From among the applications we received, these companies were selected by LSN’s scientific review board to present their technologies in an exhibition-style format while RESI attendees cast their votes on the best innovations on display. Here are the top 3 winners!

First Prize Winner: GeneSegues Therapeutics

011

GeneSegues develops novel nanocapsule based solutions that can unlock the potential of promising drugs that need more precise delivery. Our technology is highly differentiated in that our ultra-small nanocapsule is 3x smaller than competing capsules and, due to their versatility and efficiency, can be readily designed to reach more targets with more drug leading to better treatment outcomes. We are using this technology to develop our own nanoencapsulated RNA drug for head and neck and colon cancers. In addition to developing our proprietary cancer drug candidate pipeline, we are seeking to partner our nanocapsules with drug developers in other cancer indications and other disease markets in need of innovative and effective targeted delivery solutions. We are actively engaged in a number of very high potential markets in need of new delivery technologies for RNAI, gene therapy and gene editing (also known as CRISPR). Because we can create new nanocapsules more quickly and significantly smaller than the competition, we can be a leader in some of the most exciting fields in medicine today.

01

Laura Brod, CEO, GeneSegues

Second Prize Winner: GreenLight Medical

022

GreenLight Medical is a cloud-based software to streamline the introduction, evaluation, and approval of new medical technology within hospitals. GreenLight is an end-to-end solution, offering a secure, collaborative, information-exchange platform to align medical device companies, medical sales representatives, hospital providers, and physicians in one all-inclusive tool. By eliciting coordination among multiple parties on new product evaluation, data, documents, and decisions can be analyzed from one shared space. GreenLight provides the actionable data and insights needed to enable medical suppliers and hospital providers alignment on cost, quality, and outcomes regarding new medical technology introduction.

02

Austin Dirks, CEO & CO-Founder, GreenLight Medical

Third Prize Winner: Adhesys Medical

033

Surgeons still suture or staple more than they’d like to, as medical glues don’t live up to their requirements. Adhesys Medical seeks to change the game, developing one-of-its kind polyurethane-based surgical adhesives. The technology is unique as it combines ease of use, strength, flexibility and biodegradability, allowing for wound-closure on and in the body within seconds and use in unprecedented areas of surgery. Venture backed and based in the US and Germany, it is our vision to advance surgery by providing physicians with the tools to minimize complications and maximize patient comfort.

Alexander Schüller, President & Laurence Zhu, Analyst from Adhesys with Emmanuelle Schuler Head of JLABS@TMC

Alexander Schüller, President & Laurence Zhu, Analyst from Adhesys with Emmanuelle Schuler Head of JLABS@TMC

MaRS Collaborates with Life Science Nation and Johnson & Johnson Innovation to Host RESI in Toronto

12 Apr

TORONTO – April 12, 2016 – MaRS Discovery District (MaRS) is collaborating with Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) to bring the Redefining Early Stage Investments (RESI) Conference to Toronto on June 23, 2016.

The RESI Conference series brings together fundraising CEOs and early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.

“MaRS supports over 250 Canadian-grown early stage health technology startups,” said Dianne Carmichael, managing director, health innovation & venture services at MaRS. “Our goal is to provide these young emerging ventures with the best connections to investors and industry to help them scale internationally. The Redefining Early Stage Investment (RESI) conference series has a strong track record of attracting global early stage investors. We’re delighted to bring them to MaRS this summer to build on the success of our HealthKick conferences.”

RESI on MaRS will connect cutting-edge health technologies with a broad audience of investors and industry leaders, including: angel syndicates, private wealth firms, corporate venture capitalists, venture philanthropy groups, foundations and endowments, big pharma and virtual pharma companies, mid-level private equity firms, government organizations, and venture capital investors. The conference will also include 16 panel sessions with pharmaceutical, medical device, biotech, consumer health and healthcare IT investors.

The annual MaRS HealthKick Innovation Challenge will happen this year as part of RESI on MaRS. The Dragons’ Den-like Challenge sets 30 selected companies up to demonstrate their technology and business while competing for prizes in a full-day exhibition to investors and potential partners.

“The MaRS Centre in Toronto represents the 4th venue for our North American RESI Conference series. Now fundraising CEOs and scientist entrepreneurs can meet investors every 90 days — Boston took place in September (RESI Boston), San Francisco in January (RESI @ JPM), Houston is in April (RESI @ TMCx) and now Toronto in June (RESI on MaRS),” said Dennis Ford, CEO at LSN and creator of the RESI Conference Series.

Speakers and participating health ventures will be announced in April.

About MaRS Discovery District

MaRS Discovery District in Toronto is one of the world’s largest urban innovation hubs, supporting a new generation of makers and innovators who aim to make the world a better place by creating solutions that address key societal challenges. It is a community that encourages entrepreneurial thinking through education programs and events, and helps startups launch, grow and scale. MaRS supports over 1,000 ventures.

About Life Science Nation

Life Science Nation (LSN) accelerates the funding of early stage life science firms through its Match.com-like sourcing platform for private investment and enables CEOs to be more efficient in their capital-raising efforts. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series.

For more information, please contact the RESI Team at resi@lifesciencenation.com or 617-600-0668

RESI@TMCx – Program Guide

7 Apr

By Nono Hu, Director of Marketing, LSN

With 4 days to go, RESI@TMCx is getting ready to roll. We’re looking forward to being back in Houston and filling Texas Medical Center’s TMCx accelerator space with meetings, panels and new health technology ideas. With over 150 investors ready to meet with early stage companies, RESI attendees have already booked over 500 meetings. If you’re ready to plan out your day at RESI, check out the RESI@TMCx Program Guide below.

wp

RESI Panel Announcement: Large Pharma Firms Looking Externally For New Assets

7 Apr

By Christine A. Wu, Research Analyst, LSN

chrsitine

Large pharma companies are increasingly looking to early stage companies to fill their future pipelines. These firms have a variety of means of engaging with early stage companies, including in-licensing, collaborations, equity investments, and M&A. At RESI@TMCx, four senior external sourcing staff from the pharma world will explain what their firms are looking for, how they work with early stage companies, and how an emerging biotech company can position themselves to make a big pharma deal.

Moderated by Bill Kohlbrenner, CSO, Life Science Nation, the panelists are:

  • Marc Schwabish, US Head, Pharma Business Development & Licensing, Bayer
  • Barbara Araneo, Innovation Sourcing Director, Novo Nordisk
  • Joseph Simeone, Director, Business Development & Licensing, Merck
  • Mark Day, Executive Director, Head of External Research & Scouting, Alexion

RESI-Houston-2016_600

RESI Panel Announcement: Explore Houston’s Innovation Drive in The Future Is Now

7 Apr

By Lucy Parkinson, Director of Research, LSN

Houston is on a roll in life science technology. In 2015, the TMCx Accelerator ran its debut class of new healthcare companies; 2016 has already seen the arrival of JLABS@TMC, and AT&T Foundry will open in Houston soon. These facilities will collectively support dozens of new healthcare inventions, fostering a diverse ecosystem of early stage life science companies in Houston. This RESI panel, The Future Is Now, will cover these new developments and explain why Houston’s moment for has come.

Moderated by Nicole Fisher, Founder & CEO, HHR Strategies, the panel will feature:

This unique session will explore how Houston has become a health innovation hub that attracts major strategic firms to open facilities for entrepreneurs. The participants will also describe the innovation that’s happening at their new facilities in Houston, how they’re supporting new technologies that are coming out of Texas Medical Center’s instutitions, and what kinds of innovators they’re looking to work with.

If you’d like to be there in person, it’s not too late to sign up to join RESI@TMCx.

RESI-Houston-2016_600

Redefining Early Stage Investments (RESI) Conference…Get On Board the Investor Train

31 Mar

By Dennis Ford, Founder & CEO, LSN

dennis-websit

When LSN founded the Redefining Early Stage Investments (RESI) conference in 2013, it was with the simple hope of creating an event that offered more to early stage life science investors and CEOs than the other partnering events that existed at the time. LSN’s business development team had visited partnering events and investor conferences throughout the USA and also internationally, and had met few active early stage investors at these events. As LSN began to cultivate relationships with these firms and discover what kinds of technologies they were seeking to invest in, we saw the opportunity to create an event that would bring these investors together to meet with fundraising CEOs whose technologies matched their investment mandates.

We’re now approaching the 8th RESI event, and over the last three years thousands of entrepreneurs and investors have come face to face at RESI to talk about new healthcare technologies. RESI has picked up the pace every year, becoming a quarterly event for the first time in 2016.

Not only that, but RESI has hit the road; following three successful RESI events in Boston, LSN saw the opportunity to host RESI in San Francisco during the annual healthcare conference week. Organizing an event so far from our home office in Boston was a tremendous challenge that took LSN beyond our previous comfort zone, but we found that RESI was well received as a part of the annual JPM ecosystem, filling a niche for early stage companies and investors that had previously been lacking in a conference week that’s primarily geared to later stage and publicly traded companies.

Last year, RESI also expanded to Houston as a part of Texas Medical Center’s efforts to build a “Third Coast” for healthcare innovation, supported by the resources, expertise and discoveries made at their member institutions. Houston has also attracted many other strategic partners to this effort, including Johnson & Johnson’s JLABS. Being in the right place at the right time is a gift in any innovative technology endeavor, and recognizing that RESI and JLABS are now coinciding in [geography], JLABS became RESI’s title sponsor.

This summer, RESI will take another step: the first international event, held at MaRS in Toronto on June 23rd. As we’ve added new events to the RESI circuit, we’ve brought new faces into LSN’s informal network at every new venue and uncovered the unique strengths and needs of each area.

So how have we continued to build RESI’s value? One question we typically ask fundraising CEOs is how many investor meetings they’ve had in the last year. We might typically hear they’ve pitched to a dozen or more investors in one year. RESI provides an opportunity to participate in both scheduled and ad hoc meetings, and many CEOs report up to 16 -20 meetings in one day, four times per year, with active investors who are a fit for their opportunity. With the potential for over 80 meetings for those that attend every event, there aren’t any other events that offer a comparable return on effort for a CEO on the road looking for development capital. And after 7 successful events, we’ve heard from many investors that they’ve conducted due diligence on companies that they’ve met at RESI.

LSN is looking ahead to a busy year for RESI, with events lined up in Houston (April 11th), Toronto (June 23rd) and Boston (September 13th) for our ever-expanding network to come together. We’re excited to be breaking new ground and hope you’ll join us on this global investor circuit.

RESI-Houston-2016_600

RESI Panel Announcement: Family Offices

31 Mar

By Lucy Parkinson, Director of Research, LSN

Family offices often catch the interest of entrepreneurs due to the possibility of committed, long-term capital from investors who look to the long view regarding their investment decisions.  Family offices may also have unique investment motivations that relate to the family’s particular expertise and history.  With a reputation for being deep-pocketed and flexible investors, life science CEOs are often interested in meeting with family office investors, and this panel will allow the RESI@TMCx audience to learn directly from family office investment staff about how they invest, what they look for in a life science opportunity, and how to find alignment with their needs.

Moderated by Colin Widen, CEO, Boston Innovation Capital, the panelists are:

If you’re interested in listening to this panel live at RESI, you can register for RESI@TMCx now.

RESI-Houston-2016_600